Martin, Steven W.

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer

Bone health and treatmentsBone Metabolism and Diseases

Cited by 383

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Milligan, P. A., Brown, M. J., Marchant, B., Martin, S. W., van der Graaf, P. H., Benson, N., Nucci, G., Nichols, D. J., Boyd, R. A., Mandema, J. W., et al. (2013) · Clinical Pharmacology & Therapeutics

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 238

Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.

Capparelli, C., Morony, S., Warmington, K., Adamu, S., Lacey, D., Dunstan, C. R., Stouch, B., Martin, S., & Kostenuik, P. J. (2003) · Journal of Bone and Mineral Research

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 103

A mathematical model of the human menstrual cycle for the administration of GnRH analogues

Röblitz, S., Stötzel, C., Deuflhard, P., Jones, H. M., Azulay, D.-O., van der Graaf, P. H., & Martin, S. W. (2013) · Journal of Theoretical Biology

Hypothalamic control of reproductive hormonesReproductive Biology and Fertility

Cited by 54

A toxicity profile of osteoprotegerin in the cynomolgus monkey.

Smith, B. B., Cosenza, M. E., Mancini, A., Dunstan, C., Gregson, R., Martin, S. W., Smith, S. Y., & Davis, H. (2003) · International Journal of Toxicology

Bone Metabolism and DiseasesImmunotoxicology and immune responses

Cited by 33